Minute Insight: Thermo Fisher Scientific Wins FDA Clearance For Preeclampsia Blood Test
The FDA cleared Thermo Fisher’s in vitro diagnostic for preeclampsia, the leading cause of pregnancy morbidity and mortality, based on results from the PRAECIS study.
You may also be interested in...
Mirvie’s RNA platform can identify 75% of women who develop preeclampsia months before symptoms occur.
Women’s health startups focusing on areas of high unmet need such as menopause, infertility, preventive care and post-partum care will continue to attract investors in 2024. Meanwhile, machine learning and AI, as well as next-generation treatments such as psychedelic therapy, stand to drive advancements in the space.
Medtech Insight's News We're Watching highlights medtech industry news developments you may have missed over the last few weeks.